Table 3.
Late effects among testicular cancer survivors (n=785) and cancer free men (n=3,323), >5 year after diagnosis/ascertainment
| Incidence rate per 1,000 PY
|
||||
|---|---|---|---|---|
| Cases | Cancer-free men | HR* | 95%CI | |
|
| ||||
| Any late effect | 66.3 | 57.1 | 1.24 | (1.1,1.39) |
| Number of any late effects | ||||
| 1 | 3.8 | 4.0 | 1.02 | (0.66,1.57) |
| 2 | 5.9 | 5.3 | 1.28 | (0.92,1.79) |
| 3+ | 52.4 | 44.8 | 1.22 | (1.08,1.39) |
| Cardiac diseases | 22.2 | 19.8 | 1.15 | (0.94,1.41) |
| Coronary heart disease1 | 1.2 | 1.3 | 0.93 | (0.46,1.88) |
| Coronary heart disease2 | 1.3 | 1.4 | 0.88 | (0.44,1.75) |
| Myocardial infarction | 0.9 | 1.0 | 0.86 | (0.39,1.89) |
| Angina | 0.2 | 0.5 | 0.49 | (0.11,2.17) |
| Heart failure | 0.9 | 0.9 | 0.73 | (0.29,1.79) |
| Cardiomyopathy | 0.3 | 0.4 | 0.29 | (0.04,2.24) |
| Cerebrovascular disease | 0.6 | 0.9 | 0.67 | (0.23,1.95) |
| Stroke | 0.1 | 0.4 | 0.53 | (0.07,4.24) |
| Transient ischemic attack | 0.3 | 0.2 | 1.17 | (0.24,5.76) |
| Aortic aneurysm | 0.2 | 0.3 | 0.67 | (0.08,5.86) |
| Diabetes | 3.3 | 4.0 | 0.63 | (0.39,1.00) |
| Hypertension | 11.7 | 11.1 | 0.99 | (0.77,1.28) |
| Hypercholesterolemia | 6.3 | 3.9 | 1.70 | (1.19,2.41) |
| Hypertriglyceridemia | 0.7 | 0.6 | 1.00 | (0.37,2.70) |
| Metabolic syndrome | 1.7 | 1.1 | 0.97 | (0.48,1.98) |
| Obesity | 3.9 | 4.2 | 0.93 | (0.61,1.42) |
| Osteoporosis | 0.2 | 0.2 | 0.79 | (0.17,3.73) |
| Peripheral neuropathy | 4.4 | 3.0 | 1.29 | (0.84,1.98) |
| Hearing loss | 0.6 | 0.2 | 1.79 | (0.57,5.64) |
| Restrictive lung disease | 0.7 | 0.4 | 1.27 | (0.49,3.31) |
| Pulmonary embolism | 1.2 | 1.0 | 1.30 | (0.62,2.74) |
| HIV | 0.1 | 0.1 | 1.73 | (0.1,30.76) |
| Renal failure | 1.4 | 1.6 | 0.79 | (0.4,1.55) |
| Infertility | 1.7 | 0.5 | 3.13 | (1.48,6.61) |
| Dyslipidemia | 9.7 | 8.7 | 1.14 | (0.86,1.49) |
| Orchitis | 1.4 | 0.7 | 2.52 | (1.1,5.79) |
*
adjusted for race, stratified on matched group
1
includes angina and myocardial infarction
2
includes angina, myocardial infarction and heart failure